Industry News – Commitment to support nutrition research
June24, London, Ont. – Douglas Laboratories/Pure Encapsulations Canada, a subsidiary of Atrium Innovations Inc. is supporting a new comprehensive research program investigating the role of dietary supplements in managing metabolic syndrome and silent inflammation by partnering with the Institute for Nutraceuticals and Functional Foods (INAF).
The total current funding for related projects planned, and in progress, is more than $5million, and includes additional support from governmental agencies.
The research involves gaining a better understanding of metabolic syndrome and investigating the impact of nutrition on the prevention and treatment of silent inflammation associated with this condition. More specifically, this research will emphasize the health benefits of small fruits, the anti-inflammatory mechanisms of specific fish oil fractions in the prevention of cardiovascular disease (CVD), probiotics and systemic enzyme therapy in the management of inflammation and health promotion.
A person is diagnosed with metabolic syndrome when he or she displays a combination of medical conditions known to increase the risk of CVD, stroke and diabetes. Such medical conditions include obesity, excess weight, belly fat, insulin resistance, glucose intolerance, hypertension, high blood sugar andhigh cholesterol levels, as well as pro-inflammatory and pro-oxidative states.
Based at Université Laval in Quebec City, Canada, INAF dedicates all of its research efforts to advancing knowledge in the area of nutrition and health, with an expertise in studying functional food ingredients and dietary supplements.
This new research initiative is in line with Douglas Laboratories/Pure Encapsulations’ true commitment to researching, developing and manufacturing superior-quality,science-based dietary supplements that health care professionals can trust.
Moreover, Douglas Labs/Pure Encapsulations also believes it is their responsibility to provide health care professionals with new research that will lead to a better understanding of important health conditions, like those associated with the metabolic syndrome, and identify nutritional strategies that professionals can directly apply to clinical practice in a way that will help patients achieve and maintain better health.
“We have always believed in the importance of research,” said Pierre Fitzgibbon, president and CEO of Atrium Innovations, Inc. “This investment provides further indication of the depth of our commitment. Applying a more sophisticated science-based approach to our whole spectrum of products, we have the ability to positively affect the quality of life of people by helping them maintain their health and prevent serious diseases.
Formore information on this development, contact Dr. Barry W. Ritz at 610-361-2800 or by e-mail at firstname.lastname@example.org. For more information about Atrium Innovations, Inc., please visit www.atrium-innovations.com. For more information about the Canadian arm of Douglas Labs/Pure Encapsulations, please visit www.douglaslabs.ca •
Print this page